Table 3.
Compound | D4 (nM) | % inhibition at 10 µMa | |||||
---|---|---|---|---|---|---|---|
D1 (%) | D2L (%) | D2S (%) | D3 (%) | D5 (%) | |||
4b | 12.3 | <50 | |||||
4l | 14.3 | <50 | 78 | 76 | <50 | ||
4n | 10.4 | <50 | |||||
4p | 11.6 | <50 | 52 | 60 | <50 | ||
4u | 35 | <50 | |||||
4v | 18.1 | <50 | |||||
4z | 15.9 | <50 | 64 | 64 | <50 | ||
4aa | 2.2 | <50 | 94 | 93 | 70 | <50 | |
4dd | 5.4 | <50 | 87 | 82 | 70 | <50 | |
4ee | 5.2 | <50 | 78 | 76 | <50 | ||
5k | 10.4 | <50 | 83 | 79 | 51 | <50 | |
5l | 13.1 | <50 | 88 | 82 | 76 | <50 | |
5m | 10.8 | <50 | |||||
5n | 10.1 | <50 | |||||
5u | 21 | <50 | |||||
5y | 3.3 | <50 | |||||
5aa | 9.4 | <50 | |||||
5bb | 7.4 | <50 |
% inhibition values were run in duplicate in a radioligand binding assay at EuroFins (www.EuroFins.com).